A panelist discusses how health care providers can address patients’ concerns about topical treatment side effects in atopic dermatitis by providing education about proper application, expected outcomes, and the strong safety profile of modern topical medications.
A panelist discusses how the choice between systemic and topical treatments for atopic dermatitis patients should be based on factors like disease severity, affected body surface area, impact on quality of life, and previous treatment response.
A panelist discusses how this patient's history of chronic kidney disease, diabetes, and psychological stress are significant contributing factors to his prurigo nodularis, necessitating a comprehensive treatment approach that addresses both the underlying conditions and the itch-scratch cycle.
TJ Chao, MPAS, PA-C, discusses how systemic treatments for prurigo nodularis are considered for patients with moderate to severe disease, highlighting key patient-specific factors such as comorbidities and disease severity when initiating treatment.
A panelist discusses how diagnostic differentiation of prurigo nodularis requires careful examination of the characteristic firm, hyperkeratotic nodules and consideration of the patient's history of chronic pruritus and scratching behavior, while noting that comorbid atopic dermatitis may influence treatment selection toward dual-targeting therapies.
The panelist discusses how safety data from clinical trials and real-world evidence should guide physicians in prescribing ruxolitinib cream, including patient monitoring protocols and managing potential adverse effects in atopic dermatitis treatment.
The panelist discusses how to effectively communicate with patients about nonsteroidal topical treatment options for atopic dermatitis, including their benefits, proper application methods, and expected outcomes.
The panelist discusses how ruxolitinib treats atopic dermatitis by inhibiting Janus kinase (JAK)1/JAK2 signaling pathways to reduce inflammation and alleviate symptoms of the skin condition.
A panelist discusses how precision medicine enables targeted atopic dermatitis treatments by matching specific therapies to patients based on their unique disease characteristics and biomarkers
A panelist discusses how initiating topical JAK inhibitors requires thorough patient education about proper application techniques, safety monitoring, and setting realistic expectations for treatment response timelines.
A panelist discusses how supporting patients with atopic dermatitis requires addressing both physical comorbidities and psychological health challenges simultaneously for optimal treatment outcomes.
James Song, MD, FAAD, discusses how improving patient adherence to atopic dermatitis treatments requires addressing barriers such as cost, treatment complexity, and patient education, while highlighting how emerging therapies and simplified regimens may help overcome these challenges in the future.
A panelist discusses how the current treatment options for atopic dermatitis range from topical corticosteroids and calcineurin inhibitors for mild cases to systemic medications such as dupilumab and Janus kinase inhibitors for moderate-to-severe disease, with selection based on factors such as disease severity, patient age, and safety considerations.
James Song, MD, FAAD, discusses how recent advancements in atopic dermatitis treatment include targeted biologics and Janus kinase inhibitors that offer promising alternatives to traditional therapies for patients with moderate-to-severe disease.
Panelists discuss how the Effisayil 2 trial's results suggest that spesolimab offers a promising strategy for reducing the frequency and severity of GPP flares, potentially revolutionizing the management of this severe and life-threatening condition.
Panelists discuss how emerging nonsurgical options such as hedgehog pathway inhibitors, immune checkpoint inhibitors, and photodynamic therapy are expanding treatment possibilities for patients with advanced basal cell carcinoma (BCC), particularly for those unsuitable for or unresponsive to traditional surgical interventions.
Panelists discuss how the safety data from the Effisayil 2 trial show that spesolimab was generally well-tolerated, with most adverse events being mild-to-moderate, primarily consisting of injection site reactions, and no new safety concerns emerging during the study.
A panelist discusses how the treatment landscape for prurigo nodularis (PN) has evolved from primarily using topical therapies and off-label systemic medications to incorporating FDA-approved targeted biologics such as dupilumab and nemolizumab, which have demonstrated significant efficacy in reducing both the itchiness and nodular lesions.
A panelist discusses how prurigo nodularis is a chronic inflammatory skin condition that disproportionately affects middle-aged adults and those with immune disorders, causing intensely pruritic nodules that significantly impact quality of life through both physical discomfort and psychological distress.
A panelist discusses how the choice between systemic and topical treatments for pediatric atopic dermatitis (AD) depends on factors such as disease severity, impact on quality of life, affected body surface area, and response to previous therapies.
A panelist discusses how atopic dermatitis presents and is managed differently in adults vs children, with adults typically experiencing more localized lesions and chronic lichenification while children tend to have more widespread involvement and acute inflammation.
TJ Chao, MPAS, PA-C, discusses how treatment goals for prurigo nodularis should be based on disease severity and comorbidities, with adjustments to the treatment approach to optimize patient outcomes.
A collection of clinical insights on prurigo nodularis, exploring awareness and educational efforts as well as trends in treatment.
Larry Eichenfield, MD, discusses how fostering transparent communication with families affected by pediatric vitiligo involves addressing their concerns, setting realistic treatment expectations, providing emotional support, and empowering parents to be advocates for their children’s physical and emotional well-being.
Larry Eichenfield, MD, discusses how pediatric vitiligo can profoundly impact a child’s mental health, self-esteem, and social relationships, requiring a comprehensive care approach that includes psychological support, family counseling, and strategies to help children navigate peer interactions and build resilience.
Larry Eichenfield, MD, discusses how vitiligo manifests uniquely in children through its earlier onset patterns, rapid progression phases, specialized diagnostic challenges for developing skin, and modified treatment approaches that must carefully balance effectiveness with safety concerns for young patients.
Dustin Portela, DO, introduces the topic of Swift technology and how this microwave therapy is revolutionizing wart treatment by activating the immune system to fight off viral infections naturally.
Karan Lal, DO, MS, FAAD, discusses how building a collaborative care network between parents, caregivers, and school staff is crucial for successful management of pediatric atopic dermatitis through consistent treatment application, trigger avoidance, and emergency response planning.
A panelist discusses how treating pediatric atopic dermatitis requires special attention to age-appropriate therapies, family education, adherence challenges, and the impact on children’s quality of life, including sleep and social development.
Karan Lal, DO, MS, FAAD, discusses how physicians can distinguish pediatric atopic dermatitis from similar skin conditions through key clinical features such as characteristic rash distribution, intense itching, and family history of atopic diseases.
